A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
A phase 2 trial of HLX43 in cervical cancer and ovarian cancer, run by Shanghai Henlius Biotech, now recruiting.
Overview
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors is a phase 2 interventional study registered as NCT06769152 by Shanghai Henlius Biotech, with 190 participants planned, started 2025-02-20 and due to reach its primary completion in 2026-12-31. Interventions recorded: HLX43. Conditions listed: Cervical Cancer, Ovarian Cancer. No results are recorded here; the registry entry is the source.
Setting
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Recurrent/Metastatic Gynecological Malignant Tumors Failed or Intolerance to Standard First-Line Therapy
Phase
Phase 2
Sponsor
Shanghai Henlius Biotech
Registry
Enrolled
190
Similar pages
not linked directly; found by shared links- TrialA Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Shares HLX43, Shanghai Henlius Biotech.
- TrialA Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
Shares HLX43, Shanghai Henlius Biotech.